

**Table S1** Dosage and schedule of the treatment regimen

Regimen	Drug dosage	Schedule	Duration	N (%)
SOX	Oxaliplatin: 130 mg/m <sup>2</sup> IV	Day 1	Q3wk, up to 6 cycles	104 (71.72)
	S-1: 80 mg (<1.25 m <sup>2</sup> ); 100 mg (1.25–1.5 m <sup>2</sup> ); 120 mg (>1.5 m <sup>2</sup> ) PO	Days 1–14		
CapeOX	Oxaliplatin: 130 mg/m <sup>2</sup> IV	Day 1	Q3wk, up to 6 cycles	16 (11.03)
	Capecitabine: 1,000 mg/m <sup>2</sup> PO	Days 1–14		
EP	Etoposide: 100 mg/m <sup>2</sup> IV	Day 1	Q3wk, up to 4 cycles	3 (2.07)
	Cisplatin: 70 mg/m <sup>2</sup> IV	Days 1–14		
DS	Paclitaxel: 150 mg/m <sup>2</sup> IV	Days 1, 8	Q3wk, up to 4 cycles	8 (5.52)
	S-1: 80 mg (<1.25 m <sup>2</sup> ); 100mg (1.25–1.5 m <sup>2</sup> ); 120 mg (>1.5 m <sup>2</sup> ) PO	Days 1–14		
DX	Paclitaxel: 150 mg/m <sup>2</sup> IV	Days 1, 8	Q3wk, up to 4 cycles	4 (2.76)
	Capecitabine: 1,000 mg/m <sup>2</sup> PO	Days 1–14		
DC	Paclitaxel: 160 mg/m <sup>2</sup> IV	Day 1	Q3wk, up to 4 cycles	1 (0.69)
	Carboplatin: AUC 4	Day 1		
POS	Paclitaxel: 120 mg/m <sup>2</sup> IV	Day 1	Q2wk, up to 6 cycles	6 (4.14%)
	Oxaliplatin: 185 mg/m <sup>2</sup> IV	Day 1		
	S-1: 40 mg (<1.25 m <sup>2</sup> ); 50 mg (1.25–1.5 m <sup>2</sup> ); 60 mg (>1.5 m <sup>2</sup> ) PO	Days 1–7		
FOLFIRI	Irinotecan: 180 mg/m <sup>2</sup> IV	Day 1	Q2wk, up to 6 cycles	1 (0.69)
	Leucovorin: 400 mg/m <sup>2</sup> IV	Day 1		
	5-Fu: 400 mg/m <sup>2</sup> IVP	Day 1		
	5-Fu (continuous): 2,400–3,000 mg/m <sup>2</sup> IV	Days 1–2		
SEEOX	Oxaliplatin: 100 mg/m <sup>2</sup> IV	Day 1	Q3wk, up to 4 cycles	1 (0.69)
	Etoposide: 80 mg/m <sup>2</sup> IV	Day 1		
	Epirubicin: 30 mg/m <sup>2</sup> IV	Day 1		
	S-1: 80 mg (<1.25 m <sup>2</sup> ); 100 mg (1.25–1.5 m <sup>2</sup> ); 120 mg (>1.5 m <sup>2</sup> ) PO	Days 1–14		
S-1	S-1: 80 mg (<1.25 m <sup>2</sup> ); 100 mg (1.25–1.5 m <sup>2</sup> ); 120 mg (>1.5 m <sup>2</sup> ) PO	Days 1–14	Q3wk, up to 4 cycles	1 (0.69)

PO, by oral; IV, intravenous.

**Table S2 Demographic and clinicopathologic characteristics in LDG and ODG group**

Characteristics	LTG group (n=24)	OTG group (n=121)	P value
Age	60.08±9.48	60.74±9.69	0.763
BMI (kg/m <sup>2</sup> )	23.96±3.96	23.85±3.29	0.881
Gender			0.830
Male	19 (79.17)	101 (83.47)	
Female	5 (20.83)	20 (16.53)	
ASA score			0.778
1	1 (4.17)	3 (2.48)	
2	21 (87.50)	102 (85.12)	
3	2 (8.33)	15 (12.40)	
Comorbidities	10 (41.67)	36 (29.75)	0.365
Diameter in long axis (cm)	3.33±1.36	4.58±2.60	0.024
Diameter in short axis (cm)	2.58±1.17	3.60±2.33	0.039
ypTNM stage			0.603
0	1 (4.17)	12 (10.08)	
I	3 (12.50)	12 (10.08)	
II	12 (50.00)	42 (35.29)	
III	8 (33.33)	52 (43.70)	
IV	0 (0.00)	1 (0.84)	
NACT regimen			0.580
Platin-based	22 (91.67)	101 (83.47)	
Taxol-based	1 (4.17)	12 (9.92)	
Others	1 (4.17)	8 (6.61)	
Cycle of NACT			0.166
2	5 (20.83)	49 (40.50)	
3	11 (45.83)	46 (38.02)	
≥4	8 (33.3)	26 (21.49)	
Time between NACT and surgery (days)	39.67±24.62	39.64±20.43	0.996
RECIST criteria (version 1.1)			0.566
Partial response	7 (29.17)	25 (20.66)	
Stable disease	16 (66.67)	93 (76.86)	
Progressive disease	1 (4.17)	3 (2.48)	
Borrmann type			0.547
I	1 (4.17)	3 (2.48)	
II	2 (8.33)	17 (14.05)	
III	20 (83.33)	87 (71.90)	
IV	1 (4.17)	14 (11.57)	

BMI, body mass index; ASA, American Society of Anaesthesiologists; NACT, neoadjuvant chemotherapy; RECIST, Response Evaluation Criteria in Solid Tumours; LTG, laparoscopic total gastrectomy; OTG, open total gastrectomy.